免疫检查点抑制剂(ICIs)已经彻底改变了癌症治疗方式，现在已成为许多肿瘤类型(包括三阴性乳腺癌和两种诊断分类)治疗的主要手段。然而，尽管许多患者长时间持续反应，表明某些情况下具有甚至可治愈的潜力，但大多数使用ICIs的患者并没有得到实质性的益处，这凸显出需要更精确的患者选择和分层的需求。寻找预测ICIs反应的生物标志物可能在优化这些化合物的治疗应用中起到关键作用。在本文中，我们描述了目前可作为乳腺癌ICIs治疗预测因素的组织和血液标志物的现状。将这些生物标志物整合在“全面”的视角中，旨在开发多种预测因素的综合板块，将是朝着精准免疫肿瘤学迈出的重要一步。版权所有©2023年作者。由Elsevier公司出版。保留所有权利。

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable responses suggestive of an even curative potential in some cases, most patients receiving ICIs do not derive a substantial benefit, highlighting the need for more precise patient selection and stratification. The identification of predictive biomarkers of response to ICIs may play a pivotal role in optimizing the therapeutic use of such compounds. In this Review, we describe the current landscape of tissue and blood biomarkers that could serve as predictive factors for ICI treatment in breast cancer. The integration of these biomarkers in a "holistic" perspective aimed at developing comprehensive panels of multiple predictive factors will be a major step forward towards precision immune-oncology.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.